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Biological activity of tumor-treating fields in preclinical
glioma models
Manuela Silginer1, Michael Weller1, Roger Stupp2 and Patrick Roth*,1
Glioblastoma is the most common and aggressive form of intrinsic brain tumor with a very poor prognosis. Thus, novel therapeutic
approaches are urgently needed. Tumor-treating fields (TTFields) may represent such a novel treatment option. The aim of this
study was to investigate the effects of TTFields on glioma cells, as well as the functional characterization of the underlying
mechanisms. Here, we assessed the anti-glioma activity of TTFields in several preclinical models. Applying TTFields resulted in the
induction of cell death in a frequency- and intensity-dependent manner in long-term glioma cell lines, as well as glioma-initiating
cells. Cell death occurred in the absence of caspase activation, but involved autophagy and necroptosis. Severe alterations in cell
cycle progression and aberrant mitotic features, such as poly- and micronucleation, preceded the induction of cell death.
Furthermore, exposure to TTFields led to reduced migration and invasion, which are both biological hallmarks of glioma cells. The
combination of TTFields with irradiation or the alkylating agent, temozolomide (TMZ), resulted in additive or synergistic effects,
and the O6-methyl-guanine DNA methyltransferase status did not influence the efficacy of TTFields. Importantly, TMZ-resistant
glioma cells were responsive to TTFields application, highlighting the clinical potential of this therapeutic approach. In summary,
our results indicate that TTFields induce autophagy, as well as necroptosis and hamper the migration and invasiveness of glioma
cells. These findings may allow for a more detailed clinical evaluation of TTFields beyond the clinical data available so far.
Cell Death and Disease (2017) 8, e2753; doi:10.1038/cddis.2017.171; published online 20 April 2017
Glioblastomas are among the most lethal neoplasms. Despite
multimodal therapy, including maximal safe surgical resection
followed by radio- and chemotherapy, the median survival is
limited to approximately 16 months in selected patient
populations.1 The highly invasive phenotype of these tumors
precludes complete surgical resection and limits the efficacy of
other local therapies. Moreover, defects in the apoptotic
machinery of glioma cells account for their resistance to
irradiation and chemotherapy. Therefore, novel therapeutic
approaches are urgently needed.
Tumor-treating fields (TTFields) represent a novel treatment
option for glioblastoma by creating alternating electric fields
delivered through transducer arrays directly applied onto the
scalp of patients. TTFields at intermediate frequencies between
10 kHz and 1MHz circumvent the stimulation of excitable tissues
such as nerves or muscles and do not induce tissue heating.2
TTFields are supposed to exert antitumor effects by targeting
dividing tumor cells while sparing other cells in the brain that are
not undergoing division.3,4 At the beginning of mitosis, the
electric field in a cell is mostly uniform, thus oscillating electric
forces yield minimal movement on charged molecules and
dipoles. Thereby TTFields may prevent tubulin subunits to attain
correct orientation to build the mitotic spindle apparatus, so that
mitosis becomes arrested. In contrast, during cytokinesis the
electric field is non-uniform with the highest field intensity at the
furrow that is connecting the two forming daughter cells. TTFields
may therefore disturb the internal cell structure by causing
polarized molecules and organelles to move toward the furrow,
finally resulting in cell death.2,5 Moreover, preliminary data
suggest that TTFields may also exert immune-modulating
effects.6 Thus, there are various hypotheses regarding the
mechanisms thatmay contribute to the effectiveness of TTFields.
TTFields have been assessed in two phase III trials in patients
with newly diagnosed, as well as recurrent glioblastoma. In
patients with recurrent glioblastoma, TTFields had a comparable
efficacy as that seen with a 'physician’s best choice' chemother-
apy regimen while having less toxicity.7 The results of a
randomized phase III trial in patients with newly diagnosed
glioblastoma suggest that the addition of TTFields to main-
tenance temozolomide (TMZ) chemotherapy prolongs progre-
ssion-free and overall survival.8 Despite these encouraging data,
TTFields are facing a lot of skepticism from patients and
physicians, which, together with high treatment cost, has
resulted in only limited use so far.9,10 One of the major reasons
causing lowacceptance, has been the poor understanding of the
underlying biology, which may explain the exact mechanism of
action of alternating electric fields against tumors cells. The aim
of the current project was to investigate the effects of TTFields on
glioma cells including glioma-initiating cells (GICs), aswell as the
functional characterization of the underlying mechanisms.
Results
TTFields induce cell death in an intensity- and frequency-
dependent manner in human glioma cells. The human
long-term glioma cell (LTC) LN-18 or LN-229 or the human
1Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital Zurich and University of Zurich, Zurich, Switzerland and 2Department of Oncology,
University Hospital Zurich and University of Zurich, Zurich, Switzerland
*Corresponding author: P Roth, Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, Zurich 8091,
Switzerland. Tel: +41 44 255 5511; Fax: +41 44 255 4507; E-mail: patrick.roth@usz.ch
Received 23.12.16; revised 06.3.17; accepted 08.3.17; Edited by A Verkhratsky
Citation: Cell Death and Disease (2017) 8, e2753; doi:10.1038/cddis.2017.171
Ofﬁcial journal of the Cell Death Differentiation Association
www.nature.com/cddis
GIC ZH-161 or T-325 were exposed to increasing frequencies
of TTFields to define the optimal parameters for penetrating
the cell membrane. Most prominent effects on cell viability
were observed at 100 kHz (Figure 1a). This frequency was
chosen for all further experiments. Next, LN-18, LN-229,
T-325 or ZH-161 cells were exposed to increasing intensities
of TTFields. Expectedly, TTFields induced cell death in an
intensity-dependent manner, however, more extensively in
LN-18 than in LN-229 cells, with a substantial proportion of
annexin V-positive cells (Figure 1b, top, Supplementary
Figure 1a). Similarly, TTFields exposure resulted in cell death
also in the GIC lines ZH-161 and T-325 in an intensity-
dependent manner (Figure 1b, bottom, Supplementary
Figure 1b). Importantly, the whole panel of glioma cell lines,
composed of LTC and GIC, was sensitive to TTFields
treatment to a variable degree in terms of cell death induction
(Figure 1c).
TTField-induced cell death occurs in a caspase-
independent manner. Next, we aimed at assessing the
mode of cell death upon TTFields treatment in more detail.
Increased caspase activity, as determined by DEVD-amc
cleavage, was detected in cells treated with staurosporine, a
prototypic inducer of canonical, caspase-dependent apopto-
sis, but not upon exposure to TTFields. Accordingly, the
broad spectrum caspase inhibitor, zVAD-fmk, inhibited
caspase activity induced by staurosporine, but had no effect
in TTField-treated cells (Figure 2a). Furthermore, caspase-3
processing was not detected upon exposure to TTFields,
indicating that cell death induced by TTField occurs in a
caspase-independent manner. Interestingly, when LN-18,
LN-229 or ZH-161 cells were exposed to TTFields or
staurosporine, increased LC3A/B-II levels, an indicator for
the induction of autophagy, were observed (Figure 2b,
Supplementary Figure 2c). We therefore went on to examine
the morphology of TTField-induced cell death using transmis-
sion electron microscopy. TTField-exposed LN-18 or ZH-161
cells showed typical signs of autophagy such as a markedly
increased frequency of autophagosomes, mitochondria with
swollen matrices or a dilated endoplasmatic reticulum. In
contrast, staurosporine, as a classical inducer of apoptosis,
led to membrane blebbing or DNA condensation along the
nucleus and dark cytoplasm (Figure 2c). To clarify whether
autophagy in the context of TTFields acts as a survival or cell
death signal, glioma cells were cultured in the absence or
presence of the autophagy inhibitor 3-methyladenine. Block-
ing autophagy reduced the amount of dead cells upon
TTFields exposure, suggesting that autophagy mediates
TTField-induced cell death (Figure 2d, Supplementary
Figure 2a). In addition, when cells were co-treated with the
receptor-interacting protein-1 inhibitor necrostatin-1, which
blocks necroptosis, cell death induced by TTFields was partly
attenuated, suggesting that necroptosis also contributes to
cell death upon TTFields administration (Figure 2e,
Supplementary Figure 2B).
TTFields interfere with cell cycle progression. Next, we
performed cell cycle analyses, which demonstrated severe
alterations that may ultimately result in cell death. In fact, we
observed an increased number of cells in the G2/M phase
after 24 h, followed by an accumulation of cells in the sub-G1
phase after 48 h of treatment with TTFields (Figure 3a).
In line with these findings, confocal microscopy revealed an
increased number of abnormal mitotic events in TTField-
treated cells such as poly- or micronucleation. In addition,
many cells exhibited aberrant changes in cellular shape and
accumulations of actin in the nucleus, which are further
indicators of cellular stress (Figure 3b).
TTFields reduce migration and invasion of glioma cells.
As glioma cells are characterized by their ability to migrate
and invade into the surrounding healthy tissue, we asked
whether TTFields modulate their migration and invasiveness.
We observed impaired migration and invasiveness of LN-18
and LN-229 cells upon exposure to TTFields using transwell
migration and Matrigel invasion assays (Figures 4a and b).
Importantly, the effects on migration and invasion exceeded
those predicted from the loss of viable cells at the same time
(Supplementary Figure 3a). These data were further corro-
borated using a scratch wound-healing assay, which showed
reduced migration and growth toward the center of the gap of
TTField-exposed LN-18 or LN-229 cells (Figure 4c). Impor-
tantly, TTFields also interfered with the migration of the GIC
lines T-325 and ZH-161, which are thought to be of particular
importance for tumorigenesis and tumor recurrence
(Figure 4d). Again, the effects on migration of GIC were
more prominent than those expected from loss of viability
(Supplementary Figure 3b).
TTFields act in an additive or synergistic manner with
irradiation or TMZ. As radiation therapy and alkylating
chemotherapy with TMZ are part of the standard treatment
for glioblastoma patients, we assessed the activity of
TTFields in combination with these treatment modalities. In
acute cytotoxicity assays, mostly additive effects were
observed in LN-18 cells when TTFields were combined with
TMZ or irradiation, whereas synergistic effects were seen in
LN-229, T-325 or ZH-161 cells by either combination
(Figure 5a). Analyses of clonogenic survival in limiting dilution
assays revealed synergistic effects of TTFields in combina-
tion with irradiation in LN-18, as well as T-325 cells, and with
TMZ in LN-229 and ZH-161 cells (Figure 5b). Hence,
depending on the cell line, the combination approach and
the read-out, the effects may be additive or synergistic,
however, never antagonistic in the models studied here.
It is well known that the DNA repair protein O6-methyl-
guanine DNA methyltransferase (MGMT) influences the
antitumor activity of the alkylating agent, TMZ, in vivo and
in vitro.11,12 Thus, we determined a possible impact of the
cells’ MGMT status on their sensitivity to TTFields. To this end,
we used genetically engineered cells with modulated MGMT
expression. LN-18 cellswith a silencedMGMT gene or LN-229
cells overexpressing MGMT displayed similar sensitivity to
TTFields as their wild-type counterparts. Thus, TTField-
induced cell death seems to be independent from the MGMT
status (Figure 6a, Supplementary Figure 3c). Virtually all
patients relapse or progress during or after TMZ therapy,
which encouraged us to analyze whether TTFields exert
antitumor activity against TMZ-resistant glioma cells, which
had been generated by repeated exposure to TMZ.13
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Figure 1 TTFields induce cell death in an intensity- and frequency-dependent manner in human glioma cells. (a) LN-18, LN-229, T-325 or ZH-161 cells were left untreated or
exposed to TTFields (TTF; 2 V/cm) at the indicated frequencies for 48 h. Viable cell counts were obtained using trypan blue exclusion (*Po0.05). (b) The human LTC LN-18 or
LN-229 (top) or T-325 or ZH-161 GIC (bottom) were exposed to increasing intensities of TTFields as indicated for 48 h (LTC) or 72 h (GIC). Cell death was assessed by annexin
V/PI staining. (c) The LTC LN-428, LN-319, A172, U87MG, T98G or LN-308 (top) and the GIC T-269, S-24 or ZH-305 (bottom) were exposed to TTFields (2 V/cm) or not for 48 or
72 h, respectively, and subsequently analyzed for cell death by annexin V/PI staining
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TMZ-resistant LN-18 or LN-229 cells were similarly sensitive
to TTField-induced cell death as their parental counterparts
(Figure 6b), which does not point to mechanisms of
cross-resistance.
Discussion
Glioblastoma is a highly lethal brain tumor with a median
overall survival of approximately 16 months within clinical
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trials. Since 2005, the standard of care for newly diagnosed
glioblastoma has beenmaximal safe tumor resection, followed
by irradiation with concomitant and maintenance chemother-
apy with TMZ. However, the survival benefit conferred by TMZ
is largely restricted to patients with tumors that harbor a
methylation of the MGMT gene promoter.12,14 TTFields
represent a novel treatment approach that has already been
approved by FDA for newly diagnosed, as well as recurrent
glioblastoma based on the results of two phase III trials.7,8
However, there is a mismatch between the encouraging
clinical data and the biological effects of TTFields on tumor
cells, which have only been poorly understood.
Here we demonstrate that TTFields potently induce cell
death in all glioma cell lines. Importantly, TTFields treatment
displayed strong activity against glioma cells with stem-like
properties, too, which is of particular interest because of the
potential contribution of this cell population to tumor recur-
rence and therapy resistance (Figure 1).15,16 Glioblastomas
are characterized by extensive heterogeneity at a cellular and
molecular level.17,18 Owing to advances in single-cell technol-
ogy it became clear that each tumor contains multiple distinct
populations of tumor cells with variation in the expression of a
range of transcriptional programs, including oncogenic signal-
ing, proliferation, immune response and hypoxia.19 Hence,
inter- and intra-tumoral heterogeneity may contribute to the
failure of targeted therapeutic treatment strategies, which
greatly depend on the activity of certain molecular pathways.20
As TTFields are a physical rather than chemical treatment
modality, they may be effective over a wider range of tumors
with heterogeneous characteristics.5 The antitumor activity of
TTFields may depend on parameters like the cell size that may
determine the optimal frequency to induce cell death or the
cell’s doubling time as TTFields is believed to act mainly during
cellular division.5,21 Accordingly, GIC may be less responsive
to TTFields than other tumor cells because of slower
proliferation and higher heterogeneity in cell size.
In contrast to a report suggesting that HCT-116 colon cancer
cells undergo apoptosis upon TTFields treatment,22 we did not
observe caspase activation, a hallmark of apoptosis, in the cell
lines tested in this study. However, our experiments revealed
an important role for autophagy and necroptosis in TTField-
induced cell death (Figure 2). Electron microscopy further
supported the induction of autophagy, whereas no cellular
changes typically associated with apoptosis were detected.
Thus, the type of cell death induced upon TTFields treatment
may differ between tumor entities and cell lines. In line with
other studies, we observed an increased number of nuclear
aberrations in TTField-treated cells that finally result in cell
death (Figure 3).22,23 Moreover, we noticed an accumulation of
nuclear actin filaments, which has been attributed a conse-
quence of cellular stress and may have a protective role.24
Glioblastoma is characterized by highly infiltrative growth,
which precludes complete surgical resection and thus
contributes to its aggressive phenotype.25 Upon exposure to
TTFields, we found aberrant changes in the shape of glioma
cells (Figure 3), which may indicate altered cell motility.26
Accordingly, we observed reduced migration and invasion of
TTField-treated glioma cells (Figure 4). In line with these data,
reduced metastatic spread of solid tumors to the lungs by
TTFields treatment has been reported and may be a result of
impaired formation of microtubule-based processes in migrat-
ing cells.6,26,27
The combination of TTFieldswith irradiation or TMZ showed
additive or synergistic effects supporting the clinical combina-
tion of these treatment modalities as done for TMZ in one trial
(Figure 5).8 Similarly, it has been reported that combining
TTFields with drugs, such as paclitaxel or doxorubicin, may
result in reduced tumor cell proliferation and viability in
preclinical models.28,29 In our experiments, altering MGMT
expression did not influence the efficacy of TTFields, and
TMZ-resistant glioma cells remained responsive to TTFields
treatment suggesting that the mechanisms of resistance
toward TMZ, which may involve MGMT but also other
mediators13 do not overlap with a putative resistance to
TTFields (Figure 6). Accordingly, TTFields may be particularly
attractive for the majority of glioblastoma patients with tumors
that are unlikely to benefit from TMZ treatment because of the
unmethylated MGMT promoter. These findings are in line with
data demonstrating that TTFields are also active against
mitoxantrone- or doxorubicin-resistant breast cancer cells that
overexpress ABC transporters. Moreover, it was shown that
TTFields re-sensitizes drug-resistant tumor cells to che-
motherapeutic agents, a finding that was interpreted as
TTField-induced changes on the integrity of the cytoskeleton
and microtubules, as well as mitochondria distribution.29
In summary, TTFields represent a novel therapeutic
approach that has entered late-stage clinical development in
glioblastoma patients. Our data set reveals that TTFields
induce autophagy and necroptosis and interfere with the
migration and invasion of glioma cells in vitro. The additive or
synergistic effects of TTFields in combination with irradiation
or TMZ, as well as their ability to induce cell death in TMZ-
resistant glioma cells may represent a biological rationale for
the further clinical evaluation of TTFields in glioma patients.
Materials and Methods
Cells and reagents. The human LTC lines LN-18, LN-229, LN-428, LN-319,
A172 and LN-308 were kindly provided by Dr. N de Tribolet (Lausanne, Switzerland)
Figure 2 TTFields induce cell death via autophagy. (a) LN-18, LN-229 or ZH-161 cells were left untreated or exposed to TTFields (TTF, 3 V/cm), staurosporine (Stauro, 1 μM),
zVAD-fmk (10 μM) or combinations thereof for 6 h. DEVD-amc cleaving activity was determined fluorometrically (**Po0.01). (b) Whole-cell lysates of LN-18, LN-229 or ZH-161
cells, untreated or exposed to TTF (3 V/cm) or staurosporine (1 μM) for 48 h, were analyzed for full-length and cleaved caspase-3 and LC3A/B protein levels. Actin was used as a
loading control. (c) LN-18 or ZH-161 cells were left untreated or exposed to TTFields (TTF, 3 V/cm) or Stauro (1 μM) for 48 h and then monitored by electron microscopy.
Autophagosomes are indicated with white arrows, white arrowheads point to mitochondria with swollen matrices, the white star to the dilated endoplasmatic reticulum, black
arrows to membrane blebs and black arrowheads to condensed DNA along the nucleus (scale bar, 2 μm). (d) LN-18 or ZH-161 cells were treated with 3-methyladenine (3-MA,
1 mM) for 60 min followed by TTFields (2 V/cm) or not for 72 h. Cell death was assessed by annexin V/PI staining. (e) LN-18 or ZH-161 cells were treated with necrostatin-1 (Nec-
1; 100 μM) for 60 min followed by TTFields (3 V/cm) or not for 72 h. Cell death was assessed by annexin V/PI staining
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Figure 3 TTFields interfere with cell cycle progression. (a) LN-18 or LN-229 cells were exposed to TTFields (2 V/cm) for 24 or 48 h as indicated. Cell cycle analysis was
performed by flow cytometry and cell cycle distribution is shown in bar graphs, as well as flow cytometry profiles. (b) LN-18 cells were left untreated or exposed to TTFields
(2 V/cm) for 24 h. Actin (phalloidin staining, green), beta III tubulin (red) and nuclei (DAPI, blue) were analyzed by immunofluorescence. Different magnifications are shown. An
isotype control for anti-beta III tubulin is included at the bottom. Accumulations of nuclear actin are indicated with arrows, arrowheads point to altered cell shape and stars to
nuclear aberrations (scale bar, 10 μm)
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Figure 4 TTFields reduce migration and invasion of glioma cells. (a and b) LN-18 or LN-229 cells were left untreated or exposed to TTFields (2 V/cm) for 24 h. Subsequently,
modified migration/matrigel invasion Boyden chamber assays were performed to analyze migration (a) or invasion (b). Data are expressed as mean cells per field of vision (FoV)
and exemplary photographs of migrated or invaded LN-18 or LN-229 cells are shown (scale bar, 100 μm). (c) A scratch wound-healing assay was performed during which LN-18
or LN-229 cells were left untreated or exposed to TTFields (2 V/cm). After 24 h, the gap distance was imaged on a microscope and representative images are shown (scale bar,
100 μm). (d) T-325 or ZH-161 cells were left untreated or exposed to TTFields (2 V/cm) for 24 h. Subsequently, a modified migration Boyden chamber assay was performed. Data
are expressed as mean cells per FoV and exemplary photographs of migrated cells preexposed to TTFields or not are shown (scale bar, 100 μm). (**Po0.01)
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and U87MG and T98G were obtained from the American Type Culture Collection
(Manassas, VA, USA). The generation of LN-229 cells overexpressing MGMT and
LN-18 cells with a silenced MGMT gene has been described.11,30 Cells were
cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Basel,
Switzerland), containing 2 mM L-glutamine (Gibco Life Technologies, Paisley, UK),
penicillin (100 IU/ml)/streptomycin (100 μg/ml) (Sigma-Aldrich, St. Louis, MO, USA)
and 10% fetal calf serum (PAA, Vienna, Austria). The GIC lines T-269, T-325, S-24,
ZH-161 and ZH-305 were established from freshly resected tumors and cultured in
phenol red-free neurobasal medium with B-27 supplement (20 μl/ml), glutamax
(10 μl/ml) (Invitrogen), fibroblast growth factor-2 and epidermal growth factor (20 ng/
ml each; Peprotech, Rocky Hill, PA, USA).31 Cells were authenticated routinely at
the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany by short tandem repeat analysis, LTC lastly in 2013 and
GIC in 2016. Accutase was purchased from PAA. The following antibodies were
used for immunoblot analysis: caspase-3 antibody and LC3A/B antibodies were
obtained from Cell Signaling Technology (Boston, MA, USA), anti-MGMT antibody
from Alpha Diagnostics (San Antonio, TX, USA) and goat polyclonal antibody to
actin was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). zVAD-
fmk was purchased from Tocris Bioscience (Bristol, UK), 3-methyladenine from
Sigma-Aldrich, staurosporine from AppliChem (Darmstadt, Germany) and
necrostatin-1 from Merck KGaA (Darmstadt, Germany). TMZ was provided by
Merck & Co (Whitehouse Station, NJ, USA). Irradiation of cells was performed in a
co-radiation source (Gebrüder Sulzer, Thermische Energiesysteme, 60-Co,
Winterthur, Switzerland).
TTFields treatment. To study the effects of TTFields on cell cultures in vitro,
we used the inovitro system, a laboratory research device provided by Novocure
(Haifa, Israel). A cell suspension containing 20 000 cells in 200 μl medium was
seeded as a drop in the center of a glass coverslip (20 mm diameter; Thermo
Scientific, Waltham, MA, USA) within a ceramic dish. After attachment of the cells,
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Figure 5 TTFields act synergistically with irradiation or TMZ to reduce acute and clonogenic survival. (a) LN-18, LN-229, T-325 or ZH-161 cells were left untreated or
irradiated (LN-18, LN-229, 3 Gy; T-325 and ZH-161, 5 Gy) followed or not by TTFields (2 V/cm) for 24 h (left panel). Alternatively, the cells were exposed to DMSO control or TMZ
(LN-18, 100 μM; LN-229, 5 μM; T-325, 200 μM; ZH-161, 25 μM) paralleled by TTFields exposure (2 V/cm) for 24 h or not (right panel). After another 48 h, viable cells were counted
by Trypan blue exclusion test (*Po0.05; **Po0.01, relative to control cells). (b) Cells, treated as in a, were seeded at the indicated densities and clonogenic survival was
assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after 14 days
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2 ml of medium were added and the ceramic dishes were placed onto a base plate
connected to two pairs of electrodes perpendicular to each other and linked to a
sinusoid function generator and an amplifier in order to generate alternating electric
fields. The electric field intensities are expressed in V/cm root mean square.
Migration and invasion. A cell suspension containing 40 000 or 80 000
viable cells pretreated with TTFields or not for 24 h before migration or invasion,
respectively, was added to the upper well of transwell migration inserts or to BD
BioCoatTM MatrigelTM invasion chambers (pore size: 8 μm, BD Biosciences,
Franklin Lakes, NJ, USA). In the lower well, 700 μl of NIH-3T3 cell-derived
conditioned medium were used as a chemoattractant. After 16 h at 37 °C and 5%
CO2, the cells were fixed in ice-cold methanol for 10 min and stained with Mayer’s
alum hematoxylin for 60 min. Inserts were mounted in glass slides and nine fields
per sample were counted on a microscope.
Scratch wound-healing assay. Cells were seeded on Thermanox cover-
slips (Thermo Scientific). At confluency, two straight lines in perpendicular direction
were scratched into the monolayer using a 1 ml pipette tip. Cells were washed twice
to remove detached cells and then grown in serum-containing medium for additional
24 h in the absence or presence of TTFields. The gap distance was imaged on a
microscope.
Immunoblot analysis. Cells were lysed in radioimmunoprecipitation assay
buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%
sodium dodecyl sulfate) supplemented with 1x complete inhibitor mix (Roche
Diagnostics, Grenzach-Wyhlen, Germany) and phosphatase inhibitor cocktails 1
and 2 (Sigma-Aldrich) and protein levels were analyzed by immunoblot using 30 μg
of protein per lane mixed with Laemmli buffer containing β-mercaptoethanol, using
the respective antibodies. Protein bands were visualized using horseradish
peroxidase-coupled secondary antibodies (Sigma-Aldrich) and enhanced chemilu-
minescence (Perbio, Bonn, Germany).32
Viability assay. Cells, treated as indicated, were detached with accutase and
resuspended in PBS. The number of viable cells was assessed by counting the cells
with the Trypan blue dye exclusion method using a Vi-CELL Cell Viability Analyzer
(Beckman Coulter, Nyon, Switzerland).
Clonogenic survival assay. The cells were pretreated as indicated and
then seeded at the indicated densities in 96-well plates, followed by observation for
7–14 days. As a surrogate marker of viability, metabolic activity was assessed using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich).
Annexin V/propidium iodide (PI) flow cytometry. For cell death
analysis, cells were treated as indicated, followed by resuspension in annexin buffer
(10 mM HEPES, 140 nM NaCl, 2.5 mM CaCl2, pH 7.4) and staining with Pacific blue-
labeled annexin V from Biolegend (San Diego, CA, USA) and PI (Sigma-Aldrich) for
15 min at room temperature in the dark. Samples were analyzed by flow cytometry.
Annexin V- or PI-positive cells were counted as dead cells (either apoptotic or
necrotic), and the remaining cells were designated the surviving cell fraction.
Cell cycle analysis. Cells were fixed in ice-cold 70% ethanol for 1 h on ice,
subsequently washed, stained with a solution containing 0.5 mg/ml PI, 1 mg/ml
RNase A (Sigma-Aldrich) and 0.1% Triton X-100 (Sigma-Aldrich) in PBS for 30 min
at 4 °C, washed and then analyzed by flow cytometry.
Caspase activity assay. Glioma cells, exposed to TTFields or not, were
grown in phenol red-free medium. Subsequently, the cells were lysed and exposed
to 12.5 μM of the fluorescent substrate DEVD-amc (Bachem AG, Bubendorf,
Switzerland) for 1 h. Caspase activity was assessed using a Mithras microplate
reader (Berthold Technologies, Bad Wildbad, Germany).
Immunofluorescence. Cells, grown on glass-coverslips, were exposed to
TTFields or not for 24 h, and then fixed with 4% paraformaldehyde. Subsequently, the
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Figure 6 TTFields induce cell death in a MGMT-independent manner. (a) Whole-cell lysates of LN-18 puro or MGMTsi, or LN-229 neo or MGMT cells were analyzed for
MGMTexpression by immunoblot. Actin was used as a control (top). The cells were exposed to TTFields (2 V/cm) or not for 48 h and analyzed for cell death by annexin V/PI
staining. (b) LN-18 parental or TMZ-resistant, or LN-229 parental or TMZ-resistant cells were exposed to TTFields (2 V/cm) or not. After 48 h cell death was analyzed by annexin
V/PI staining
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cells were washed with 0.1% Triton X-100 (Sigma-Aldrich), blocked in 5% BSA and
incubated with anti-beta III tubulin antibody (Abcam, Cambridge, UK) (diluted 1:20) or
isotype control overnight at 4 °C, followed by an incubation with a goat anti-rabbit IgG-
Alexa Fluor 594-coupled secondary antibody (Invitrogen) (diluted 1:100) and nuclear
DNA labeling with DAPI (Invitrogen). Finally, the cells were stained with Alexa Fluor
488 phalloidin (Thermo Scientific), diluted 1:20, at room temperature for 20 min.
Images were acquired using a Leica SP5 confocal microscope (Wetzlar, Germany).
Transmission electron microscopy. The cells including supernatant
were fixed in a 2x fixation solution (2.5% glutaraldehyde and 1.6% formalaldehyde
in a 100 mM sodium cacodylate buffer, pH 7.4, final concentration), dehydrated in a
graded ethanol series and embedded into Epon. Sections of 60 nm were imaged
with a Tecnai Spirit transmission electron microscope (FEI, Hillsborough, OR, USA).
Statistical analysis. Data are presented as means and S.D. The experiments
shown were commonly repeated three times. For some studies, representative
experiments are shown. Analysis of significance was performed using a two-tailed
Student’s t-test (Excel, Microsoft, Redmond, WA, USA) (*Po0.05, **Po0.01).
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